A detailed history of Principal Financial Group Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 10,590 shares of ALT stock, worth $83,449. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,590
Holding current value
$83,449
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

BUY
$5.91 - $10.23 $62,586 - $108,335
10,590 New
10,590 $70,000
Q4 2021

Feb 09, 2022

SELL
$8.69 - $12.48 $986,393 - $1.42 Million
-113,509 Closed
0 $0
Q3 2021

Nov 09, 2021

SELL
$8.43 - $16.81 $16,708 - $33,317
-1,982 Reduced 1.72%
113,509 $1.28 Million
Q2 2021

Aug 10, 2021

SELL
$9.85 - $16.46 $585,749 - $978,826
-59,467 Reduced 33.99%
115,491 $1.14 Million
Q1 2021

May 10, 2021

BUY
$12.71 - $24.31 $169,373 - $323,955
13,326 Added 8.24%
174,958 $2.47 Million
Q4 2020

Feb 08, 2021

BUY
$7.84 - $14.22 $1.27 Million - $2.3 Million
161,632 New
161,632 $1.82 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $386M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.